457 related articles for article (PubMed ID: 25463548)
1. MDA5 plays a critical role in interferon response during hepatitis C virus infection.
Cao X; Ding Q; Lu J; Tao W; Huang B; Zhao Y; Niu J; Liu YJ; Zhong J
J Hepatol; 2015 Apr; 62(4):771-8. PubMed ID: 25463548
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
Vazquez C; Tan CY; Horner SM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31534039
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage.
Welsch C; Haselow K; Gouttenoire J; Schneider M; Morikawa K; Martinez Y; Susser S; Sarrazin C; Zeuzem S; Antes I; Moradpour D; Lange CM
J Hepatol; 2015 Apr; 62(4):779-84. PubMed ID: 25463536
[TBL] [Abstract][Full Text] [Related]
4. Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.
Johnson CL; Owen DM; Gale M
J Biol Chem; 2007 Apr; 282(14):10792-803. PubMed ID: 17289677
[TBL] [Abstract][Full Text] [Related]
5. Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0.
Horner SM; Park HS; Gale M
J Virol; 2012 Mar; 86(6):3112-20. PubMed ID: 22238314
[TBL] [Abstract][Full Text] [Related]
6. EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway.
Zhu C; Xiao F; Hong J; Wang K; Liu X; Cai D; Fusco DN; Zhao L; Jeong SW; Brisac C; Chusri P; Schaefer EA; Zhao H; Peng LF; Lin W; Chung RT
J Virol; 2015 Jul; 89(13):6608-18. PubMed ID: 25878102
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity.
Ding Q; Cao X; Lu J; Huang B; Liu YJ; Kato N; Shu HB; Zhong J
J Hepatol; 2013 Jul; 59(1):52-8. PubMed ID: 23542348
[TBL] [Abstract][Full Text] [Related]
8. Limited suppression of the interferon-beta production by hepatitis C virus serine protease in cultured human hepatocytes.
Dansako H; Ikeda M; Kato N
FEBS J; 2007 Aug; 274(16):4161-76. PubMed ID: 17651439
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity.
Nitta S; Sakamoto N; Nakagawa M; Kakinuma S; Mishima K; Kusano-Kitazume A; Kiyohashi K; Murakawa M; Nishimura-Sakurai Y; Azuma S; Tasaka-Fujita M; Asahina Y; Yoneyama M; Fujita T; Watanabe M
Hepatology; 2013 Jan; 57(1):46-58. PubMed ID: 22911572
[TBL] [Abstract][Full Text] [Related]
10. Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.
Kalkeri G; Lin C; Gopilan J; Sloan K; Rijnbrand R; Kwong AD
Antimicrob Agents Chemother; 2013 Sep; 57(9):4417-26. PubMed ID: 23836176
[TBL] [Abstract][Full Text] [Related]
11. GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS.
Chen Z; Benureau Y; Rijnbrand R; Yi J; Wang T; Warter L; Lanford RE; Weinman SA; Lemon SM; Martin A; Li K
J Virol; 2007 Jan; 81(2):964-76. PubMed ID: 17093192
[TBL] [Abstract][Full Text] [Related]
12. Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons.
Anggakusuma ; Frentzen A; Gürlevik E; Yuan Q; Steinmann E; Ott M; Staeheli P; Schmid-Burgk J; Schmidt T; Hornung V; Kuehnel F; Pietschmann T
J Virol; 2015 Apr; 89(7):3833-45. PubMed ID: 25609814
[TBL] [Abstract][Full Text] [Related]
13. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.
Liang Y; Ishida H; Lenz O; Lin TI; Nyanguile O; Simmen K; Pyles RB; Bourne N; Yi M; Li K; Lemon SM
Gastroenterology; 2008 Nov; 135(5):1710-1718.e2. PubMed ID: 18725224
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus NS3/4A protease blocks IL-28 production.
Ding Q; Huang B; Lu J; Liu YJ; Zhong J
Eur J Immunol; 2012 Sep; 42(9):2374-82. PubMed ID: 22685015
[TBL] [Abstract][Full Text] [Related]
15. [Chronic hepatitis C virus infection attenuates host antiviral innate immune response].
Oshiumi H; Matsumoto M; Seya T
Nihon Rinsho; 2015 Feb; 73(2):234-8. PubMed ID: 25764676
[TBL] [Abstract][Full Text] [Related]
16. Differential, type I interferon-mediated autophagic trafficking of hepatitis C virus proteins in mouse liver.
Desai MM; Gong B; Chan T; Davey RA; Soong L; Kolokoltsov AA; Sun J
Gastroenterology; 2011 Aug; 141(2):674-85, 685.e1-6. PubMed ID: 21683701
[TBL] [Abstract][Full Text] [Related]
17. DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture.
Grünvogel O; Esser-Nobis K; Reustle A; Schult P; Müller B; Metz P; Trippler M; Windisch MP; Frese M; Binder M; Fackler O; Bartenschlager R; Ruggieri A; Lohmann V
J Virol; 2015 Oct; 89(20):10548-68. PubMed ID: 26269178
[TBL] [Abstract][Full Text] [Related]
18. Long Noncoding RNA ITPRIP-1 Positively Regulates the Innate Immune Response through Promotion of Oligomerization and Activation of MDA5.
Xie Q; Chen S; Tian R; Huang X; Deng R; Xue B; Qin Y; Xu Y; Wang J; Guo M; Chen J; Tang S; Li G; Zhu H
J Virol; 2018 Sep; 92(17):. PubMed ID: 29899107
[TBL] [Abstract][Full Text] [Related]
19. Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length.
Kell A; Stoddard M; Li H; Marcotrigiano J; Shaw GM; Gale M
J Virol; 2015 Nov; 89(21):11056-68. PubMed ID: 26311867
[TBL] [Abstract][Full Text] [Related]
20. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.
Ahlén G; Derk E; Weiland M; Jiao J; Rahbin N; Aleman S; Peterson DL; Pokrovskaja K; Grandér D; Frelin L; Sällberg M
Gut; 2009 Apr; 58(4):560-9. PubMed ID: 18689426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]